Arun Krishna, Vice President and franchise head for an AstraZeneca US OBU, shares details of a treatment option with TAGRISSO® (osimertinib). AstraZeneca is focused on the development of new treatments, prioritizing researching options in eligible patients.

Listen to the full podcast episode to learn more.

Please see Important Safety Information for TAGRISSO.

Please see complete Prescribing Information, including Patient Information for TAGRISSO.

Arun Krishna, Vice President and franchise head for an AstraZeneca US OBU, shares details of a treatment option with TAGRISSO&reg; (osimertinib). AstraZeneca is focused on the development of new treatments, prioritizing researching options in eligible patients.
Listen to the full podcast episode to learn more.
Please see <a href="https://www.fiercepharma.com/fiercepharmacom/important-safety-information-tagrisso">Important Safety Information</a> for TAGRISSO.
Please see complete <a href="https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/52503580-1192-44f7-a05e-5743159ed19b/52503580-1192-44f7-a05e-5743159ed19b_viewable_rendition__v.pdf">Prescribing Information</a>, including Patient Information for TAGRISSO.

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Arun Krishna, VP and franchise head for an AstraZeneca US OBU, discusses a treatment option for patients.

An additional treatment option with TAGRISSO® (osimertinib) (Sponsored)

Walgreens is emerging as a real-world evidence partner for the biopharma industry, according to a new episode of The Top Line, sponsored by Walgreens. In the conversation, Deepak Kuletha, who leads data management and analytics for the company’s biopharma services division, explains how Walgreens’ 9 million daily interactions and nationwide footprint generate rich insights into patient behavior, access barriers and therapy performance in the real world. Kuletha shares examples of how Walgreens helps pharma partners optimize drug launches, identify early adoption patterns, uncover affordability challenges and improve patient support programs—ultimately enabling faster, evidence-based decision-making.

As real-world evidence grows more complex, Kuletha highlights how Walgreens’ advanced data management, privacy safeguards and emerging analytics tools—including machine learning and AI—help cut through the noise. These capabilities allow the pharmacy chain to synthesize de-identified data into actionable insights that reveal adherence risks, surface gaps in treatment understanding, and support earlier interventions. For life sciences professionals looking to understand how retail pharmacies are shaping the future of evidence generation, the episode offers a compelling inside look at the collaboration opportunities ahead. Listen to the full conversation to hear how Walgreens is turning scale into smarter, proactive patient care.

Walgreens is emerging as a real-world evidence partner for the biopharma industry, according to a new episode of The Top Line, sponsored by Walgreens. In the conversation, Deepak Kuletha, who leads data management and analytics for the company&rsquo;s biopharma services division, explains how Walgreens&rsquo; 9 million daily interactions and nationwide footprint generate rich insights into patient behavior, access barriers and therapy performance in the real world. Kuletha shares examples of how Walgreens helps pharma partners optimize drug launches, identify early adoption patterns, uncover affordability challenges and improve patient support programs&mdash;ultimately enabling faster, evidence-based decision-making.
As real-world evidence grows more complex, Kuletha highlights how Walgreens&rsquo; advanced data management, privacy safeguards and emerging analytics tools&mdash;including machine learning and AI&mdash;help cut through the noise. These capabilities allow the pharmacy chain to synthesize de-identified data into actionable insights that reveal adherence risks, surface gaps in treatment understanding, and support earlier interventions. For life sciences professionals looking to understand how retail pharmacies are shaping the future of evidence generation, the episode offers a compelling inside look at the collaboration opportunities ahead. Listen to the full conversation to hear how Walgreens is turning scale into smarter, proactive patient care.

Walgreens’ Deepak Kuletha joins The Top Line to discuss how pharmacy data insights uncover patient barriers, helping drugmakers improve access, boost adherence and drive better outcomes.

From data to decisions: how Walgreens is powering smarter pharma strategies (Sponsored)

Uncertainty reigned early this year with the inauguration of President Donald Trump and his threats to impose tariffs and slash prescription drug prices. But as players in the biopharma industry have gotten a better handle on the impact of these measures and the overall investment landscape, valuations have become more predictable and dealmakers have focused on larger, lower-risk acquisitions. The recent trends bode well for the business development landscape in 2026 and beyond.

In this week’s episode of “The Top Line,” Arda Ural, EY Americas life sciences sector leader, joins Fierce Pharma’s Kevin Dunleavy to discuss the dealmaking landscape in the biopharma industry. They dig into the Federal Trade Commission’s scrutiny of M&A transactions, revitalized therapeutic areas, artificial intelligence investment and the emergence of China as an innovation powerhouse.

To learn more about the topics in this episode: 
2025 M&A up in value and deal count after year of 'conservatism and recovery': Leerink Partners
After a 'reset' year for M&A, expect bigger deals in 2025: reports

Uncertainty reigned early this year with the inauguration of President Donald Trump and his threats to impose tariffs and slash prescription drug prices. But as players in the biopharma industry have gotten a better handle on the impact of these measures and the overall investment landscape, valuations have become more predictable and dealmakers have focused on larger, lower-risk acquisitions. The recent trends bode well for the business development landscape in 2026 and beyond.
In this week&rsquo;s episode of &ldquo;The Top Line,&rdquo; Arda Ural, EY Americas life sciences sector leader, joins Fierce Pharma&rsquo;s Kevin Dunleavy to discuss the dealmaking landscape in the biopharma industry. They dig into the Federal Trade Commission&rsquo;s scrutiny of M&amp;A transactions, revitalized therapeutic areas, artificial intelligence investment and the emergence of China as an innovation powerhouse.
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercebiotech.com/biotech/2025-ma-value-and-count-after-year-conservatism-and-recovery-leerink-partners">2025 M&amp;A up in value and deal count after year of 'conservatism and recovery': Leerink Partners</a></li>
<li><a href="https://www.fiercepharma.com/pharma/after-reset-year-ma-expect-bigger-deals-2025-ey-report">After a 'reset' year for M&amp;A, expect bigger deals in 2025: reports</a></li>
</ul>

The biopharma dealmaking landscape and what to expect in 2026

Marker 05

In this episode of Health Matters, GCI Health’s Ryan Kuresman and Health@WPP’s Wendy Lund explore the fast-shifting landscape of cancer care with Pam Traxel of the American Cancer Society Cancer Action Network. Traxel outlines the growing complexity facing patients—from navigating an expanding range of treatment options to managing rising costs.

The conversation also examines the evolving role of patient advocacy and the partnerships needed to drive meaningful change. Traxel emphasizes the importance of integrating lived experiences into policy, improving the credibility of patient-facing communication and strengthening early, ongoing collaboration between biopharma, policymakers and advocacy organizations. For healthcare and life sciences professionals seeking deeper insight into how access, innovation and policy must intersect to improve patient outcomes, this is a must-listen episode.

In this episode of Health Matters, GCI Health&rsquo;s Ryan Kuresman and Health@WPP&rsquo;s Wendy Lund explore the fast-shifting landscape of cancer care with Pam Traxel of the American Cancer Society Cancer Action Network. Traxel outlines the growing complexity facing patients&mdash;from navigating an expanding range of treatment options to managing rising costs.
The conversation also examines the evolving role of patient advocacy and the partnerships needed to drive meaningful change. Traxel emphasizes the importance of integrating lived experiences into policy, improving the credibility of patient-facing communication and strengthening early, ongoing collaboration between biopharma, policymakers and advocacy organizations. For healthcare and life sciences professionals seeking deeper insight into how access, innovation and policy must intersect to improve patient outcomes, this is a must-listen episode.

ACS CAN’s Pam Traxel joins WPP’s Wendy Lund to unpack what patients need most amid growing complexity in cancer care.

An additional treatment option with TAGRISSO® (osimertinib) (Sponsored)

In 1 playlist(s)

The Top Line

Social links

Follow podcast

Recent clips